Company Overview and News

26
Agios (AGIO) Initiates Phase III Study on PK Deficiency Drug

2018-06-20 zacks
Agios Pharmaceuticals, Inc. (AGIO - Free Report) , announced the initiation of the phase III ACTIVATE study which will evaluateits lead rare genetic diseases candidate, AG-348 in patients with Pyruvate kinase (PK) deficiency who do not receive regular blood transfusions. The ACTIVATE study will enroll about 80 adult patients with PK deficiency who do not receive regular blood transfusions. The ACTIVATE study aims to demonstrate that treatment with AG-348 leads to a sustained increase in hemoglobin in these patients.
ANIP AGLE AGIO ILMN

9
Agios Announces Initiation of Global Phase 3 Trial (ACTIVATE) of AG-348 in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused

2018-06-18 globenewswire
CAMBRIDGE, Mass., June 18, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the initiation of the Phase 3 ACTIVATE trial evaluating AG-348, a first-in-class, selective, small molecule activator of the pyruvate kinase-R (PKR) enzyme. ACTIVATE is a randomized, placebo-controlled trial that will enroll approximately 80 adults with pyruvate kinase (PK) deficiency who do not receive regular blood transfusions.
AGIO

111
Agios Pharmaceuticals, Inc.Stock Is an Analyst Darling for Good Reason

2018-06-05 investorplace
As Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) closes at new highs, analysts are gushing over the company’s prospects. The company earned eight buy recommendations and just one hold in the last four months. What is it about Agios stock that has the experts bullish on the company?
WFC WFCNP WFC.WS CELGZ AGIO WFC.PRL CRSP WFC.PRJ WFC.PRT WFC.PRR JNCE WFC.PRQ WFC.PRP WFC.PRO WFC.PRN CELG WFC.PRY WFC.PRX WFC.PRW WFC.PRV

11
AGIO / Agios Pharmaceuticals, Inc. FORM 8-K (Current Report)

2018-06-04 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
AGIO

65
New Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Azacitidine Demonstrate Robust Responses and a Well Tolerated Safety Profile in Newly Diagnosed IDHm AML Patients

2018-06-04 globenewswire
- ORR of 78%, CR Rate of 44% and CR/CRi/CRp Rate of 65% in the Ivosidenib Arm; Molecular Clearance Observed in 7 Out of 21 Patients -
CELGZ AGIO CELG

9
Agios Pharmaceuticals (AGIO) Up 13.4% Since Earnings Report: Can It Continue?

2018-06-04 zacks
A month has gone by since the last earnings report for Agios Pharmaceuticals, Inc. (AGIO - Free Report) . Shares have added about 13.4% in that time frame.
AGIO

9
Updated Data from Ivosidenib Phase 1 Dose-Escalation and Expansion Trial in IDH1m Relapsed or Refractory AML Continue to Show Durable Responses as a Single Agent

2018-06-02 globenewswire
- In 179 Relapsed or Refractory IDH1m AML Patients, Primary Endpoint of CR+CRh Rate of 31.8% with a Median Duration CR+CRh of 8.2 Months -
AGIO

65
Agios Presents Data from Phase 1 Dose-Escalation Study of AG-881 in Patients with IDH Mutant Positive Advanced Glioma and Other Solid Tumors

2018-06-01 globenewswire
- Favorable Safety Profile at Dose Levels Below 100 mg; 10 mg and 50 mg Doses Under Evaluation in Recently Initiated Glioma Perioperative Study -
CELGZ AGIO CELG

11
AGIO / Agios Pharmaceuticals, Inc. FORM 8-K (Current Report)

2018-06-01 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
AGIO

71
Agios (AGIO) Progressing Well on Pipeline Amid Competition

2018-05-25 zacks
We issued an updated research report on Agios Pharmaceuticals, Inc. (AGIO - Free Report) on May 23.
LGNZZ AGIO CELG LGND LGNYZ LGNXZ ILMN LGNDZ TLRD

76
Agios to Present New Clinical Data from its IDH Programs at ASCO

2018-05-16 globenewswire
– Updated Data From Ivosidenib Phase 1 Expansion in IDH1m R/R AML and the First Data from the AG-881 Phase 1 Study in IDHm Glioma to be Highlighted in Oral Presentations –
CELGZ FDC AGIO CELG

23
With $87 Million in Hand, Beam Therapeutics Launches to Fight Disease with CRISPR Base Editing Te...

2018-05-14 biospace
Beam Therapeutics, a new precision genetic medicines company, launched this morning with $87 million in a Series A funding round backed by F-Prime Capital Partners and ARCH Venture Partners.
EDIT AGIO

245
A Fresh Look At Celgene After Q1 And New Info On Ozanimod

2018-05-08 seekingalpha
The company's sales growth is stellar, but pipeline and management issues are weighing on it, plus biotech's known big-picture concerns.
XLRN GILD JUNO GOOGL CELG AGIO AAPL BGNE

25
Agios (AGIO) Q1 Loss Wider than Expected, Revenues Miss

2018-05-07 zacks
Agios Pharmaceuticals, Inc. (AGIO - Free Report) posted first-quarter 2018 loss of $1.63 per share, wider than the Zacks Consensus Estimate of a loss of $1.60 and the year-ago loss of $1.56.
TXN UNP LGNZZ AGIO LGND LGNYZ LGNXZ PTGX ILMN LGNDZ

9
Agios Pharmaceuticals' (AGIO) CEO David Schenkein on Investor Day 2018 Results - Earnings Call Transcript

2018-05-06 seekingalpha
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Investor Day 2018 Results Earnings Conference Call May 4, 2018 8:00 AM ET
HGRL AGIO

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

7h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

8h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

CUSIP: 00847X104